Back to top
more

Vanda Pharmaceuticals (VNDA)

(Real Time Quote from BATS)

$7.20 USD

7.20
100,820

-0.09 (-1.24%)

Updated Apr 9, 2026 11:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Intercept (ICPT) Ocaliva Gains Conditional Approval in EU

by Zacks Equity Research

Intercept (ICPT) Ocaliva, in combination with UDCA, was approved in the EU for the treatment of PBC.

    Zacks Equity Research

    Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls

    by Zacks Equity Research

    Gilead (GILD) has been ordered to pay $2.5 billion in royalties to Merck (MRK) in the largest patent infringement dispute in the history of the U.S.

      Zacks Equity Research

      Roche (RHHBY) to Terminate Pacifica Bioscience Agreement

      by Zacks Equity Research

      Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.

        Zacks Equity Research

        Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis

        by Zacks Equity Research

        Incyte (INCY) and Eli Lilly (LLY) announced that the EMA's CHMP has issued a positive opinion for the approval of Olumiant (baricitinib).

          Zacks Equity Research

          Ionis (IONS) Receives Milestone Payment from AstraZeneca

          by Zacks Equity Research

          Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.

            Zacks Equity Research

            Agios Stops Development of PKR Activator AG-519, Stock Falls

            by Zacks Equity Research

            Shares of Agios (AGIO) tanked 19.4% after the company decided to discontinue the development of its PKR activator, AG-519.

              Zacks Equity Research

              Abbott Labs to Close St. Jude Acquisition Later this Week

              by Zacks Equity Research

              Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.

                Zacks Equity Research

                Immunomedics Completes Enrollment In Cancer Drug Study

                by Zacks Equity Research

                Immunomedics (IMMU) achieved the planned enrollment in a phase II study on IMMU-132.

                  Zacks Equity Research

                  Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate

                  by Zacks Equity Research

                  Cempra (CEMP) announced that it received a CRL from the FDA relating to its new drug applications for oral and intravenous formulation of candidate solithromycin.

                    Zacks Equity Research

                    Prima (PBMD) Reports Favorable Initial Melanoma Study Data

                    by Zacks Equity Research

                    Prima (PBMD) announced interim data from the TACTI-mel program on IMP321 for the treatment of patients with unresectable or metastatic melanoma.